Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group

BACKGROUND: Patients with resistant focal segmental glomerulosclerosis (FSGS) who are unresponsive to corticosteroids and other immunosuppressive agents are at very high risk of progression to end stage kidney disease. In the absence of curative treatment, current therapy centers on renoprotective i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Nephrol
Main Authors: Trachtman, Howard, Vento, Suzanne, Herreshoff, Emily, Radeva, Milena, Gassman, Jennifer, Stein, Daniel T., Savin, Virginia J., Sharma, Mukut, Reiser, Jochen, Wei, Changli, Somers, Michael, Srivastava, Tarak, Gipson, Debbie S.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4511259/
https://ncbi.nlm.nih.gov/pubmed/26198842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-015-0094-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados